Type “Obamacare” into Google News and 997,000 results are returned in just over two tenths of a second.

The headlines run the gamut of supportive to critical to blind naivety to borderline hostile. At the end of the day, it is not really surprising that some media organizations with reputations for being overtly liberal provide favorable coverage of Obamacare while more conservative publications deride the president’s health care law.

What is not up for debate is that 7 out of every 10 Americans surveyed by Bankrate.com believe Obamacare is either harming the U.S. or doing nothing to help the country.

It also cannot be debated that despite all the ongoing controversy that has surrounded Obamacare for several years now, the iShares U.S. Healthcare Providers ETF (NYSEArca: IHF) remains one of the more impressive health care ETFs. [Obamacare ETF Tries to Skirt Controversy]

Although biotechnology stocks and exchange traded funds are rebounding a bit, this is not January or February when the daily lists of ETFs hitting all-time highs were populated by funds such as the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) and the Health Care Select Sector SPDR (NYSEArca: XLV).

However, IHF was among the ETFs making new highs Wednesday. IHF did struggle in the first three weeks of April, falling 6.2% from its early April peak to its April 17 trough.